Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,522 shares of the pharmaceutical company’s stock after selling 4,760 shares during the quarter. Martingale Asset Management L P’s holdings in Vertex Pharmaceuticals were worth $14,303,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Vertex Pharmaceuticals by 1.0% in the third quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock worth $9,484,293,000 after acquiring an additional 243,088 shares in the last quarter. Capital Research Global Investors increased its holdings in Vertex Pharmaceuticals by 2.8% in the third quarter. Capital Research Global Investors now owns 16,553,281 shares of the pharmaceutical company’s stock worth $6,482,978,000 after purchasing an additional 444,990 shares in the last quarter. Capital International Investors increased its holdings in Vertex Pharmaceuticals by 77.9% in the 3rd quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock worth $1,836,550,000 after buying an additional 2,053,156 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Vertex Pharmaceuticals by 10.7% in the 2nd quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock worth $1,949,228,000 after acquiring an additional 424,808 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in shares of Vertex Pharmaceuticals by 1.7% in the second quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock worth $1,697,716,000 after acquiring an additional 65,047 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 2.9%

Vertex Pharmaceuticals stock opened at $478.13 on Friday. The stock has a market cap of $121.46 billion, a P/E ratio of 31.19, a price-to-earnings-growth ratio of 2.10 and a beta of 0.31. The company has a fifty day simple moving average of $469.68 and a 200-day simple moving average of $437.20. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. During the same period in the previous year, the business posted $3.98 earnings per share. The business’s revenue was up 9.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Citigroup lifted their target price on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Royal Bank Of Canada cut their price objective on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research report on Friday, February 13th. Morgan Stanley raised their price target on shares of Vertex Pharmaceuticals from $570.00 to $596.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $577.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Twenty-three investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $553.36.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $600, signaling meaningful upside from current levels and adding institutional momentum. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00
• Positive Sentiment: Bank of America reiterated/issued a bullish view that the stock is positioned to rise, supporting demand from fundamental analysts. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Bank of America Analyst Says
• Positive Sentiment: Citigroup likewise published a positive forecast for VRTX, adding to the cluster of buy-side endorsements. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: Morgan Stanley projected strong price appreciation, further cementing a consensus of elevated analyst expectations. Morgan Stanley Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
• Positive Sentiment: Truist raised its price target to $525 and kept a buy rating, another near‑term upside signal from a major sell‑side shop. Benzinga
• Positive Sentiment: News reports show the stock recently spiked (up ~9–10%) on an analyst upgrade, indicating momentum-driven buying can be swift. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: Clinical catalyst: a Vertex drug reduced proteinuria in a Phase III IgA nephropathy trial — a meaningful development that could expand the pipeline and long‑term revenue potential. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Neutral Sentiment: Vertex presented at Barclays’ healthcare conference (transcript available) — useful for detail on pipeline timelines and management guidance but not an immediate price mover by itself. Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage note: articles report a rising biotech weighting/focus in Nasdaq indexes, which can support longer‑term passive demand for VRTX but is not an immediate earnings catalyst. Vertex Pharmaceuticals (NASDAQ:VRTX) Biotech Focus Rises In Nasdaq Index
• Negative Sentiment: Despite the bullish notes, the stock has pulled back and printed a larger intraday decline than the market in recent sessions, reflecting profit‑taking and short‑term volatility. Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
• Negative Sentiment: Some commentary flagged that while price moves have been strong, recent earnings‑estimate revision trends may limit near‑term follow‑through. Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

Insider Activity

In related news, EVP Ourania Tatsis sold 260 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $126,451.00. Following the sale, the executive vice president owned 46,763 shares of the company’s stock, valued at approximately $22,743,185.05. This represents a 0.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark E. Bunnage sold 620 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $301,537.00. Following the sale, the executive vice president directly owned 7,284 shares of the company’s stock, valued at $3,542,573.40. This represents a 7.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 91,156 shares of company stock valued at $42,845,497 in the last three months. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.